Brief: Orexo's Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development

Orexo AB

05/07/2022 07:04

July 5 (Reuters) - Orexo AB  ORX.ST :
    * OREXO'S NASAL ADRENALINE RESCUE MEDICATION OX640 ENTERS
CLINICAL
DEVELOPMENT
    * DEVELOPMENT AND COMMERCIAL PARTNERSHIPS ARE CONSIDERED
    * STUDY AIMS TO DETERMINE RELATIVE BIOAVAILABILITY AND
ABSORPTION
CHARACTERISTICS OF INVESTIGATIONAL OX640 FORMULATIONS VERSUS AN
INTRAMUSCULAR ADRENALINE INJECTION IN HEALTHY VOLUNTEERS
    * COSTS RELATED TO STUDY ARE INCLUDED IN COMPANY'S OPEX
GUIDANCE
FOR 2022
    * INITIATED FIRST EXPLORATIVE HUMAN CLINICAL STUDY
(OX640-001) FOR
OX640, AN ADRENALINE RESCUE MEDICATION WITH NASAL DELIVERY

Source text for Eikon:  ID:nWkr93FJc 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))